TB-500: structure, nomenclature and handling

Thymosin beta-4 is a 43-residue polypeptide and one of the most abundant members of the beta-thymosin family. In molecular terms its defining property is that it binds monomeric actin — the globular form of the cytoskeletal protein — and the region responsible for that binding has been mapped to a short internal stretch of the sequence.

That stretch is the heptapeptide leucine-lysine-lysine-threonine-glutamate-threonine-glutamine, written LKKTETQ in single-letter code. It sits in the central portion of the parent sequence and is frequently described as the actin-binding motif. Because it is short, it can be made by standard solid-phase synthesis without the difficulties that attach to producing a 43-residue chain.

The research code TB-500 is applied in practice both to the full-length 43-residue peptide and to the synthetic heptapeptide fragment, usually with the fragment's amino terminus acetylated. The two are not close in size. The full-length peptide has a molecular weight of roughly 4,900 daltons; the acetylated heptapeptide sits near 890 daltons. A mass measurement therefore separates them unambiguously, which is why the certificate rather than the label is the document that settles which entity is in the vial.

The material is catalogued as TB-500, TB500, thymosin beta-4, thymosin β4 and Tβ4, and the fragment specifically as Ac-LKKTETQ or the actin-binding domain. Thymosin beta-4 as a defined entity carries CAS 77591-33-4; the acetylated fragment is generally listed under a separate registry entry, reflecting that it is a different compound.

The beta-thymosin naming is worth separating from the alpha-thymosins. Thymosin alpha-1 is an unrelated 28-residue peptide with a different sequence and a different biochemical description, and the shared word in the two names points to a common tissue of origin in the original isolation work rather than to any structural relationship. Listings that treat them as variants of one compound are mistaken.

As with most short synthetic peptides, the material is typically isolated as an acetate salt, which affects the mass weighed out without altering identity.

Mass spectrometry confirms the intact molecular mass and, for this compound in particular, resolves the identity question described above. An observed mass near 890 daltons and one near 4,900 daltons are both entirely consistent with a certificate headed TB-500, and only one of them corresponds to any given order.

High-performance liquid chromatography resolves the main peak from related substances and produces the purity figure. In a short synthetic sequence the most common related substances are deletion sequences, where a residue failed to couple during synthesis, and truncated chains. In a long one the same failures are more numerous and harder to separate, which is one practical reason the two entities are not equivalent to work with even where both are pure.

HEEZ Research supplies this compound in a single format: a 10 mg lyophilized vial. There is no second strength in the current catalogue, so the format decision that arises with two-size products does not apply here.

The material is supplied as a lyophilized powder. Freeze-drying removes water and leaves the peptide as a solid, markedly more stable than the same peptide in solution, and stable enough at ambient temperature to ship without refrigeration in transit.

Reconstitution converts the dried cake into a working solution, and it is a standard laboratory step rather than a product specification. Which solvent is used, and at what final concentration, is determined by the protocol in force at the receiving facility.

What HEEZ specifies is the contents of the vial. The material is supplied in a single 10 mg lyophilized format, stated on the label and on the batch certificate of analysis, and the certificate records the molecular weight for the batch — the figure a molar protocol requires.

Sealed lyophilized material is ambient-stable for the duration of transit, so no cold chain or insulated packaging is required for shipping. On receipt the lyophilized TB-500 vial goes to refrigeration and is kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify. Solutions are generally treated as short-lived compared with the lyophilized form, and repeated freeze-thaw cycling is avoided.

The sequence contains no cysteine and no methionine, which removes two of the more common oxidation routes that complicate storage for other peptides. Threonine and glutamine residues are present, and glutamine is subject to slow deamidation in solution over time — a further reason solutions are made up as needed rather than held.

The certificate records what an independent facility measured for one specific batch. Its value lies in being batch-specific, so the first check is that the lot number on the document matches the vial in hand.

The identity section is the one that matters most for this compound. It compares observed molecular mass against a stated theoretical mass, and reading which theoretical figure was used tells the reader whether the batch is the heptapeptide fragment or the full-length peptide. That is information the product name alone does not carry.

The purity figure is the HPLC main-peak area as a percentage of total peak area, and the attached chromatogram shows how it was arrived at. Whether the impurities are a few discrete peaks or a broad cluster suggests different synthesis problems, which is why the trace is worth looking at rather than the headline number alone.

Peptide content, or net peptide content, is sometimes reported separately. It accounts for counter-ions and residual water, and it is the figure determining how much actual peptide a nominal 10 mg represents.